CSNK2A1 Pilot Grant Program

CSNK2A1 Pilot Grant Program

Status: ACTIVE
Funder: University of Pennsylvania’s School of Medicine: Orphan Disease Center (ODC)
Amount: US $50,000
Last Updated: March 21, 2026

Summary

Overview

Note: All applicants must first submit a Letter of Interest (LOI) (indicated above as Letter of Inquiry) to be reviewed for consideration of a full application submission.Full applications will be by invitation only following LOI review. The Orphan Disease Center The Orphan Disease Center is part of the University of Pennsylvania’s School of Medicine. Mission The Orphan Disease Center will develop transformative therapies using platform technologies that can be deployed across multiple rare diseases. We will emphasize disorders with substantial unmet need independent of their incidence and will strive to assure access to patients of all populations. Through our grants, Programs of Excellence, JumpStart programs, and a number of new initiatives, the ODC seeks to drive therapeutic development for rare diseases. We help identify and fund the most promising therapeutics while also tackling obstacles present in rare disease drug development. CSNK2A1 Pilot Grant Program The CSNK2A1 Foundation is pleased to announce the CSNK2A1 Pilot Grant Program, which will support one (1) investigator-initiated research project aimed at advancing the biological understanding of OCNDS and/or accelerating the discovery or development of therapeutic approaches. This pilot grant is intended to generate high-impact preliminary data, support novel or underexplored approaches, and position investigators for future external funding. Research Priorities The RFA is intentionally focused. Proposed projects must be clearly relevant to OCNDS and CSNK2A1 biology and align with one or more of the priority areas below. Community input has identified speech and communication, intellectual disability, sleep disturbances, and anxiety as high-priority symptom domains, and proposals that help advance understanding or treatment of these areas are encouraged. Priority will be given to projects that address: Disease mechanisms and variant-level biologyBiomarker discovery or validationTherapeutic approaches

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.